Johanna Mercier | President And Head Of U.S., France, Germany And Japan Commercial Markets
Bristol Myers Squibb

Johanna Mercier, President And Head Of U.S., France, Germany And Japan Commercial Markets, Bristol Myers Squibb

Johanna Mercier is President and Head of U.S. Commercial at Bristol-Myers
Squibb, a position she assumed in October 2017. Johanna has national
oversight and financial responsibility of a complex organization delivering $12B
in revenue annually. In this leadership role, Johanna strives to instill a balance
of innovation and accountability among the 2,500 employees working to deliver
transformational medicines from the company’s oncology, cardiovascular, and
immunoscience portfolios. Johanna is a patient focused leader who is also
actively engaged with the health care policy and the advocacy community to
ensure the affordability and access of prescription medicines for Americans.
Johanna’s career at Bristol-Myers Squibb spans 25 years with strong national
and international experiences. After over a decade in sales and marketing in
Canada, she went on to lead world wide and market teams across both the US
and Europe. As General Manager of UK and Ireland, Johanna achieved double
digit growth while implementing a new operating model. As President of
Worldwide Markets for Europe, Australia and Canada, she led international
markets driving $4B in revenue and overseeing 1700 employees. She
successfully navigated complex reimbursement processes in the region securing
patient access for the company’s immuno-oncology portfolio in highly costsensitive
Johanna is chair of the Bristol-Myers Squibb Employee Political Advocacy Fund
for Innovation (EPAF) and a member of the Healthcare Leadership Council (HLC).
She is a staunch advocate for diversity and inclusion and a sought after mentor.
Johanna holds a science degree from the University of Montreal, and an M.B.A.
from Concordia University, Montreal.


Immunotherapy Conference Day 2 @ 10:00

Panel discussion: Commercial strategies in immunotherapy

  • High level pharma companies come together to discuss their strategies for tackling cancer
last published: 17/Jan/19 11:45 GMT

back to speakers